ClinicalTrials.gg
CompletedNCT02216084Updated May 5, 2021

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

A Phase 1 interventional study of Recombinant ADAMTS13 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP), sponsored by Baxalta now part of Shire. Completed at 11 sites in 7 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-05.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda — 3 open to participants now, 4 under way, 1 of them phase 3. Purpura, Thrombotic Thrombocytopenic · Takeda.

Started
2014
the only one that year
Phase 1
Only one
of the 10
Registered
1st of 10
by date

Among the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, this one is the only one that started in 2014, is the only one in phase 1, and was the 1st registered.

Purpura, Thrombotic Thrombocytopenic

67 studies on the registry are indexed under Purpura, Thrombotic Thrombocytopenic; 18 are open to participants now.

Browse Purpura, Thrombotic Thrombocytopenic studies →

Open to participants now

3 of the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 16 Purpura, Thrombotic Thrombocytopenic studies recruiting now, 12 (75%) set no upper age limit and 1 (6%) stops at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, or all of them as a file.
02

Study summary

The purpose of this Phase 1, prospective, uncontrolled, open-label, multicenter, dose-escalation study is to evaluate the safety, including immunogenicity, and pharmacokinetics of BAX930 (rADAMTS13) in a total of 14 evaluable subjects diagnosed with severe hereditary thrombotic thrombocytopenic purpura (TTP) (plasma ADAMTS13 activity \<6%) who are assigned to one of three dose cohorts.

03

Conditions studied

  • Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is between 12 and 65 years of age, inclusive. (The first 2 subjects in any cohort will be ≥ 18 years of age.)
  • Subject and/or legally authorized representative has provided written .
  • Subject has a documented diagnosis of severe hereditary ADAMTS13 deficiency, defined as 1) confirmed by genetic testing, documented in patient history or at screening, and 2) ADAMTS13 activity \< 6%, documented in patient history or at screening. NOTE: In patients receiving prophylactic therapy with fresh frozen plasma (FFP) or other ADAMTS13 containing products, the levels of plasma ADAMTS13 activity may exceed 6% at screening.
  • Cryoprecipitate, FFP, or other ADAMTS13 containing products interfering with ADAMTS13 PK have to be paused at least 10 days prior to infusion of the product.
  • The subject is not displaying any severe TTP symptoms at screening. Patients presenting with minor, but stable laboratory abnormalities (LDH not higher than 3 times the ; count not lower than 100,000 per μl) at screening may be enrolled.
  • Subjects ≥18 years of age have a score ≥ 60%, and subjects \< 18 years of age have a Lansky score ≥ 70%.
  • Subject is virus negative (HCV-) as confirmed by antibody or polymerase chain reaction (PCR) testing; HCV positive (HCV+) subjects are eligible for inclusion if their disease is chronic but stable.
  • If female of , subject presents with a negative serum pregnancy test and agrees to employ adequate measures for the duration of the study.
  • Subject is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has been diagnosed with any other TTP-like disorder (for example, microangiopathic hemolytic anemia), including acquired TTP.
  • Subject has known to hamster proteins or other components of the product.
  • Subject has a medical history or presence of a functional neutralizing ADAMTS13 inhibitor at screening.
  • Subject has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis/mild asthma, food allergies or animal allergies.
  • Subject has a medical history of hematological disorders, in particular systemic lupus erythematosus, amyloidosis, antiphospholipid antibody syndrome, vasculitis, other hemolytic anemia, disseminated intravascular coagulation, and systemic scleroderma.
  • Subject has a history of significant neurological events, such as major stroke, indicating that a relapse might have severe consequences, as judged by the investigator.
  • Subject is positive with an absolute \< 200/mm3.
  • Subject has been diagnosed with a cardiovascular disease [ (NYHA) classes 3-4].
  • Subject is scheduled to undergo elective surgery during study participation.
  • Subject has been diagnosed with severe liver disease, as evidenced by, but not limited to, any of the following: serum 3 times the , (INR) > 1.5, hypoalbuminemia, portal vein hypertension (e.g. presence of otherwise unexplained splenomegaly, history of esophageal varices).
  • Subject has been diagnosed with severe glomerular disease, with gross proteinuria and a serum creatinine level ≥ 2.5 mg/dL.
  • Subject has been treated with an immunomodulatory drug, in case of corticoids with an equivalent to hydrocortisone greater than 10 mg /day, excluding topical treatment (e.g. ointments, nasal spray), within 30 days prior to enrollment.
  • Subject has a history of drug and/or alcohol abuse within the last 6 months prior to study enrollment.
  • Subject has a of less than 3 months.
  • Subject is identified by the investigator as being unable or unwilling to cooperate with study procedures.
  • Subject is a family member or employee of the investigator.
  • Subject suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude.
  • If female, subject is pregnant or lactating at the time of study enrollment.
  • Subject has participated in another clinical study involving an investigational product or device within 30 days prior to study enrollment.
  • Subject is scheduled to participate in another clinical study involving an investigational product or device during the course of this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Recombinant ADAMTS13

    The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 3 subjects; Cohort 2: 3 subjects; Cohort 3: 8 subjects\]. Subjects will be enrolled and dosed sequentially. Subjects will be recruited to the next dose level only after short-term safety has been demonstrated and reviewed by an independent Data Monitoring Committee (DMC) at the preceding dose level. The first 2 subjects in any cohort will be ≥ 18 years of age. The effects of the investigational product on vital signs, hematology, and clinical chemistry parameters (up to 96 ± 2 hrs blood sampling timepoint) will determine short-term safety. The DMC will recommend whether to proceed with the study or in case of a safety concern recommend remedial actions and/or to discontinue the study. Subject participation will continue until 28 ± 3 days after infusion of the investigational product. Subject participation in one Dose Cohort (1-3) is expected to be approximately 6-8 weeks.

    Drug: Recombinant ADAMTS13

Interventions

  • rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection. Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3).

06

What researchers measure

Primary outcomes

  1. Occurrence of adverse events (serious and non-serious), including the incidence of binding and inhibitory antibody formation

    Time frame: Up to 28 (± 3) days after investigational product infusion

Secondary outcomes

  1. Pharmacokinetic [PK] parameter 'incremental recovery [IR]'

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

  2. PK parameter 'maximum concentration following infusion [Cmax]'

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

  3. PK parameter 'minimum time to reach Cmax [T max]'

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

  4. PK parameter 'terminal or disposition half-life [T1/2]'

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

  5. PK parameter 'mean residence time [MRT]'

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

  6. PK parameter 'systemic clearance [Cl]'

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

  7. PK parameter 'area under the plasma/time curve [AUC]'

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

  8. PK parameter 'steady state volume of distribution [Vss]'

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

  9. Plasma von Willebrand factor: Ristocetin cofactor activity [VWF:RCo], von Willebrand factor antigen [VWF:Ag] and VWF structure analysis

    Will be evaluated after single infusions of rADAMTS13 in Dose Cohorts 1, 2 and 3

    Time frame: Within 1 hour pre-infusion and up to 288 (± 4) hours post-infusion

07

Study locations

11 sites
  • Ohio State University Medical Center
    Dublin, Ohio 43017, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • The Methodist Hospital Research Institute
    Houston, Texas 77030, United States
  • General Hospital Vienna (Allgemeines Krankenhaus der Stadt Wien)
    Vienna, 1090, Austria
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinikum Jena
    Jena, 07743, Germany
  • • Tokyo Medical and Dental University Hospital, Faculty of Medicine
    Bunkyo-ku, Tokyo, 113-8519, Japan
  • Hyogo College of Medicine Hospital, Department of Hematology
    Nishinomiya-shi, 663-8501, Japan
  • Institute of Hematology and Transfusion Medicine
    Warsaw, 02776, Poland
  • Inselspital - Universitaetsspital Bern
    Bern, 3010, Switzerland
  • University College London Hospital NHS Foundation Trust
    London, NW1 2BU, United Kingdom
08

References and documents

Publications

  • Scully M, Knobl P, Kentouche K, Rice L, Windyga J, Schneppenheim R, Kremer Hovinga JA, Kajiwara M, Fujimura Y, Maggiore C, Doralt J, Hibbard C, Martell L, Ewenstein B. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017 Nov 9;130(19):2055-2063. doi: 10.1182/blood-2017-06-788026. Epub 2017 Sep 14. PubMed 28912376 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Feb 2016, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2014
First posted
Aug 13, 2014
StartActual
Sep 30, 2014
Primary completionActual
Feb 22, 2016
CompletionActual
Feb 22, 2016
Last update
May 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02216084
Responsible party
Sponsor
First posted
Aug 13, 2014
Start date
Sep 30, 2014
Primary completion
Feb 22, 2016
Completion
Feb 22, 2016
Last update
May 5, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apadamtase alfa

Start the discussion